All In MedTech

Device Trial Radar · NCT04836546

Eversense® Non-adjunctive Use Post Approval Study

A Post Approval Study to Evaluate the Safety and Effectiveness of the Eversense® Continuous Glucose Monitoring (CGM) System Used Non-adjunctively

Last checked: Nov 19, 2026Latest source record: Aug 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

925

Planned (sponsor's estimate)

Start

Apr 13, 2021

Primary completion

Mar 31, 2026

Study completion Mar 31, 2026

Sponsor

Lead sponsor
Senseonics, Inc.Public (SENS)
Sponsor type
Industry
First posted
Apr 8, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a non-blinded, prospective, multi-center, single arm longitudinal cohort study (patient serving as their own control), to evaluate the effectiveness of diabetes with the Eversense CGM System non-adjunctively compared to self-monitoring of blood glucose (SMBG) using a blood glucose (BG) meter in participants with either Type 1 or Type 2 diabetes. Subjects will serve as their own control, with their baseline based on using SMBG to manage their diabetes for the first 6 months followed by using Eversense CGM System non-adjunctively for the second 6 months. Total follow-up duration is 12 months. The investigation will include both clinic visits and home use of Eversense CGM System. The nonadjunctive phase will have two sensors, up to 90-day duration, inserted sequentially. All care decisions specific to diabetes will be based on blood glucose (BG) values in the first phase and the Eversense CGM system values in the second phase.

Conditions

  • Diabetes

Interventions

  • Blood glucose meterDevice

    First phase: SMBG for 6 months

  • Eversense CGM SystemDevice

    Second phase: CGM for 6 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of moderate and severe hypoglycemic and diabetic ketoacidosis eventsTime frame: First 6 months (phase 1) compared to second 6 months (phase 2)

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • LA Universal Research Center, Inc.

    Los Angeles, California

  • Denver Endocrinology, Diabetes & Thyroid Center

    Englewood, Colorado

  • CMR of Greater New Haven

    Hamden, Connecticut

20 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.